Grabar Law Office is investigating securities fraud claims against four companies: ASP Isotopes for allegedly making false statements about uranium enrichment technology; Integer Holdings for overstating competitive position and concealing sales deterioration; Molina Healthcare for failing to disclose adverse medical cost trends; and Soleno Therapeutics for misrepresenting the safety profile of its drug candidate DCCR, which resulted in a patient death.
Molina Healthcare, Inc. (MOH)
Common Stock · Currency in USD · XNYS
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Company Info
SIC6324
Composite FIGIBBG000MBHNC8
CIK0001179929
IPOJul 2, 2003
Sectorhospital & medical service plans
Highlights
Market Cap$7.26B
EPS$6.04
P/E Ratio22.98
Revenue$45.81B
Gross Profit$5.73B
Net Income$316.00M
Employees19,000
WSO52,091,073
Phone(562) 435-3666
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Molina Healthcare, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Molina Healthcare, Inc. (MOH) has returned -19.90% so far this year and -59.27% over the past 12 months. Looking at the last ten years, MOH has achieved an annualized return of 7.95%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
MOH
1M-6.33%
6M-31.03%
YTD-19.90%
1Y-59.27%
5Y-10.34%
10Y7.95%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Molina Healthcare, Inc. (MOH) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.21% | -13.44% | -12.09% | 4.78% | ||||||||
| 2025 | 5.22% | -2.46% | 8.78% | -1.21% | -6.01% | -1.35% | -46.76% | 13.51% | 5.54% | -20.44% | -2.78% | 17.08% |
| 2024 | -1.64% | 11.06% | 4.73% | -16.34% | -7.87% | -4.71% | 14.62% | 1.72% | -1.64% | -7.13% | -7.42% | -2.85% |
| 2023 | -4.64% | -11.60% | -2.23% | 9.66% | -8.81% | 10.34% | 1.66% | 1.73% | 5.03% | 1.83% | 10.13% | -0.98% |
| 2022 | -7.90% | 5.06% | 8.98% | -6.61% | -8.36% | -4.05% | 17.30% | 3.54% | -2.10% | 7.98% | -5.93% | -2.36% |
| 2021 | -0.64% | 0.91% | 6.71% | 9.12% | -1.36% | 0.22% | 7.54% | -1.51% | 0.91% | 9.04% | -3.77% | 9.94% |
| 2020 | -9.58% | -0.89% | 13.14% | 22.23% | 9.31% | -4.23% | 2.72% | -1.09% | -2.34% | 2.16% | 7.83% | 2.72% |
| 2019 | 15.64% | 1.44% | 4.50% | -9.55% | 9.69% | -1.29% | -7.94% | -1.52% | -14.85% | 6.76% | 13.91% | -0.26% |
| 2018 | 19.14% | -20.95% | 12.48% | 1.90% | 1.55% | 14.00% | 6.53% | 14.20% | 7.67% | -15.28% | 1.90% | -17.71% |
| 2017 | 4.55% | -14.98% | -7.00% | 9.43% | 29.92% | 7.02% | -3.52% | -4.83% | 7.72% | -1.70% | 15.35% | -2.19% |
| 2016 | -19.31% | -6.52% | 3.01% | 13.96% | -5.13% | 8.66% | -6.04% | -3.04% | 3.20% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Molina Healthcare, Inc. (MOH) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MOH compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Molina Healthcare, Inc. volatility is 2.54%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 15.56B | 15.63B | 14.89B | 12.31B | 12.21B | 9.53B | 6.79B | 7.15B | 8.47B | 7.45B | 6.58B | 4.48B | 3.00B | 1.93B |
| Equity Attributable To Parent (USD) | 4.07B | 4.50B | 4.22B | 2.96B | 2.63B | 2.10B | 1.96B | 1.65B | 1.34B | 1.65B | 1.56B | 1.01B | 892.94M | 782.31M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 4.07B | 4.50B | 4.22B | 2.96B | 2.63B | 2.10B | 1.96B | 1.65B | 1.34B | 1.65B | 1.56B | 1.01B | 892.94M | 782.31M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | - | - | 440.45M | 79.02M | 50.00M |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | 1.45B | 1.41B | 851.55M | 737.00M | 274.47M |
| Noncurrent Liabilities (USD) | 4.12B | 3.24B | 2.51B | 2.50B | 2.53B | 2.47B | 1.56B | 1.26B | 1.58B | 1.23B | 1.20B | 1.29B | 816.02M | 324.47M |
| Current Liabilities (USD) | 7.37B | 7.90B | 8.17B | 6.86B | 7.05B | 4.97B | 3.27B | 4.25B | 5.56B | 4.57B | 3.82B | 2.17B | 1.29B | 828.04M |
| Liabilities (USD) | 11.50B | 11.13B | 10.68B | 9.35B | 9.58B | 7.44B | 4.83B | 5.51B | 7.13B | 5.80B | 5.02B | 3.47B | 2.11B | 1.15B |
| Other Non-current Assets (USD) | - | - | - | - | - | - | - | 451.00M | 618.00M | 1.01B | 877.00M | 891.04M | 671.19M | 364.25M |
| Fixed Assets (USD) | - | - | - | - | - | - | - | 241.00M | 342.00M | 454.00M | 393.00M | 340.78M | 292.08M | 221.44M |
| Noncurrent Assets (USD) | 3.12B | 2.86B | 2.35B | 2.23B | 2.15B | 1.66B | 820.00M | 692.00M | 960.00M | 1.46B | 1.27B | 1.23B | 963.27M | 585.70M |
| Other Current Assets (USD) | 8.91B | 9.47B | 9.44B | 7.78B | 7.89B | 6.20B | 4.56B | 5.13B | 6.64B | 5.01B | 4.71B | 2.65B | 1.74B | 1.20B |
| Accounts Receivable (USD) | 3.53B | 3.30B | 3.10B | 2.30B | 2.18B | 1.67B | 1.41B | 1.33B | 871.00M | 974.00M | 597.00M | 596.46M | 298.94M | 149.68M |
| Current Assets (USD) | 12.44B | 12.77B | 12.54B | 10.08B | 10.06B | 7.88B | 5.97B | 6.46B | 7.51B | 5.99B | 5.31B | 3.25B | 2.04B | 1.35B |
| Assets (USD) | 15.56B | 15.63B | 14.89B | 12.31B | 12.21B | 9.53B | 6.79B | 7.15B | 8.47B | 7.45B | 6.58B | 4.48B | 3.00B | 1.93B |
News and Insights
Grabar Law Office is investigating shareholder claims against four companies for alleged breaches of fiduciary duties and securities fraud. Corcept Therapeutics faces allegations of misrepresenting clinical trial data for its relacorilant drug, which received an FDA Complete Response Letter. Integer Holdings is accused of overstating its competitive position and concealing deteriorating sales. Kyndryl Holdings disclosed SEC investigations into cash management practices and internal control weaknesses. Molina Healthcare allegedly failed to disclose adverse medical cost trends and guidance risks.
The healthcare transportation service market is expected to grow from $116.47 billion in 2026 to $155.26 billion by 2030, with a CAGR of 7.5%. Growth drivers include aging populations, chronic disease prevalence, home healthcare expansion, and AI-powered route optimization. Leading companies include Centene, Molina Healthcare, DHL, ARAMARK, Lyft Healthcare, and ModivCare, with North America currently dominant and Asia-Pacific showing fastest growth.
Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday?negative
U.S. stock indices rallied Friday with the Dow Jones surging nearly 2% to a fresh all-time high of 49,870 points, while the Russell 2000 outperformed with a 3% gain. The software-driven sell-off paused after eight consecutive down sessions, with tech stocks rebounding sharply. However, Molina Healthcare crashed 29% on weak earnings guidance, and Amazon fell over 7% despite beating earnings expectations due to concerns over capital expenditures.
Molina Healthcare (NYSE:MOH) shares plunged 33.3% to $118 in after-hours trading following Q4 earnings. The company reported a loss of $2.75 per share, missing analyst expectations of 33 cents, though revenue of $11.38 billion beat estimates. For fiscal 2026, Molina expects adjusted EPS of at least $5 and premium revenue of approximately $42 billion, down 2% from 2025. CEO Joseph Zubretsky noted that 2026 is expected to be a trough year for Medicaid industry margins.
Michael Burry, famous for betting against the housing market, liquidated his UnitedHealth stake in Q3 2025 and rotated heavily into Molina Healthcare, calling it a 'generational buy.' While major insurers faced steep losses following a low 2027 Medicare rate proposal from CMS, Molina fared better than peers due to its 75% Medicaid revenue exposure and disciplined operations. Burry's contrarian bet appears to be paying off early in 2026.
The Centers for Medicare & Medicaid Services (CMS) proposed a 2027 Medicare Advantage payment increase of only 0.09%, significantly below Wall Street's expectations of 4-6%. This modest growth announcement triggered sharp declines in major health insurer stocks, with UnitedHealth, Humana, and CVS Health leading the losses. The CMS emphasized program sustainability and payment accuracy through updated risk adjustment models.
Michael Burry and Cathie Wood are taking divergent investment approaches in uncertain markets. Burry is betting on Molina Healthcare as an undervalued defensive play in government-backed healthcare programs, comparing it to early-stage GEICO. Meanwhile, Wood is allocating capital toward innovation-driven technologies, recently acquiring positions in Broadcom, Joby Aviation, and Archer Aviation through her ARK ETFs.
On December 30, 2025, major U.S. stock indexes closed near record highs with modest declines in quiet year-end trading. The S&P 500 fell 0.13%, Nasdaq dropped 0.24%, and the Dow eased 0.20%. Boeing led industrials with a 0.6% gain following an $8.5 billion U.S. Air Force contract announcement, while Molina Healthcare jumped 2.5% on positive investor commentary. OceanFirst Financial plunged 6.7% after announcing a merger agreement.
Renowned investor Michael Burry published a detailed investment thesis on Substack arguing that Molina Healthcare is a premier investment opportunity, comparing it favorably to Warren Buffett's acquisition of Geico. Burry highlighted Molina's focus on Medicaid programs, impressive growth potential, and high returns on invested capital, suggesting it has better business prospects than Apple. He noted the company's best-in-class loss ratio, expense ratio, and conservative accounting under CEO Joe Zubretsky, and believes MOH stock could be a generational buy if it falls below $100.